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Background:  In  the  UK,  despite  the  import  and  use  of all forms  of  asbestos  being  banned  more  than  15 years
ago,  the incidence  of mesothelioma  continues  to  rise.  Mesothelioma  is almost  invariably  fatal,  and  more
research  is  required,  not  only  to ﬁnd  more  effective  treatments,  but also  to achieve  an  earlier  diagnosis
and  improve  palliative  care.  Following  a debate  in  the  House  of  Lords  in July 2013,  a package  of  measures
was  agreed,  which  included  a  James  Lind Alliance  Priority  Setting  Partnership,  funded  by  the National
Institute  for Health  Research.  The  partnership  brought  together  patients,  carers,  health  professionals  and
support organisations  to agree  the top  10 research  priorities  relating  to the  diagnosis,  treatment  and  care
of patients  with  mesothelioma.
Methods:  Following  the  established  James  Lind  Alliance  priority  setting  process,  mesothelioma  patients,
current  and  bereaved  carers,  and  health  professionals  were  surveyed  to  elicit  their  concerns  regarding
diagnosis,  treatment  and  care.  Research  questions  were  generated  from  the survey  responses,  and  follow-
ing  checks  that  the  questions  were  currently  unanswered,  an  interim  prioritisation  survey  was  conducted
to identify  a shortlist  of questions  to take  to  a ﬁnal  consensus  meeting.
Findings:  Four  hundred  and  ﬁfty-three  initial  surveys  were  returned,  which  were  reﬁned  into  52  unique
unanswered  research  questions.  The  interim  prioritisation  survey  was  completed  by  202  responders,
and  the  top  30 questions  were  taken to  a ﬁnal  meeting  where  mesothelioma  patients,  carers,  and  health
professionals  prioritised  all the  questions,  and  reached  a consensus  on the  top  10.
Interpretation:  The  top  10 questions  cover  a  wide  portfolio  of  research  (including  assessing  the  value
of  immunotherapy,  individualised  chemotherapy,  second-line  treatment  and  immediate  chemotherapy,
monitoring  patients  with  pleural  thickening,  deﬁning  the  management  of ascites  in  peritoneal  mesothe-
lioma,  and  optimising  follow-up  strategy).  This  list  is an invaluable  resource,  which  should  be  used to
inform  the  prioritisation  and  funding  of future  mesothelioma  research.
rs.  Pu© 2015  The  Autho
. IntroductionMesothelioma is a malignant disease that can develop in
he pleural membranes around the lungs, and, less often, in the
eritoneum. Virtually all cases of mesothelioma occur as the result
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of exposure to asbestos, and although, in the UK, the import and
use of amosite and crocidolite were banned in 1985 and chrysotile
in 1999, the incidence of mesothelioma continues to rise. In 2012
there were 2535 new cases [1], and the peak is now predicted
to be reached around the year 2022 [2]. Although the increasing
incidence reﬂects the increasing number of groups at risk [3], the
pattern of disease remains similar, with around 85% of patients
being male, the majority of cases affecting the pleura, and, typi-
cally, symptoms appearing on average 30–40 years after exposure
to asbestos. Once diagnosed the median survival is 9–12 months
[4], and although the ultimate aim is to ﬁnd a cure, progress to
extend the survival and improve the quality of life of patients has
been slow. The use of extrapleural pneumonectomy within a mul-
timodality approach has now been largely abandoned in Europe
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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ollowing the results of the Mesothelioma and Radical Surgery
MARS) trial [5]. Radiotherapy is mainly used in a palliative setting
nd the value of prophylactic radiotherapy, to avoid cancer cell
eeding along surgical tracts, is currently being investigated in two
andomised trials [6,7]. Although chemotherapy has been shown
o give a small survival beneﬁt in patients with a good perfor-
ance status [8], the disease, in virtually all patients, will progress.
herefore the future is likely to lie in translational research, where
here have been some encouraging insights into tumorigenesis,
iomarkers, and immune response [9–12]. However in the mean-
ime, patients experience delays in diagnosis, limited treatment
ptions and many debilitating symptoms and side effects [13,14].
The UK Parliament identiﬁed mesothelioma research as a pri-
rity area for the Department of Health, following a debate in the
ouse of Lords in July 2013 [15]. A package of measures was agreed,
hich included a James Lind Alliance (JLA) Priority Setting Partner-
hip (PSP), funded by the National Institute for Health Research
NIHR) to identify patients’, carers’, health professionals’ and sup-
ort organisations’ priorities for mesothelioma research. The JLA,
hich was established in 2004, is a non-proﬁt making initiative,
osted by the NIHR, with the aim of helping to achieve meaningful
atient and clinician involvement in research priority setting and to
nsure that those who conduct and fund health research are aware
f the gaps in knowledge that matter most to patients, caregivers,
nd clinicians [16,17]. The aim of a JLA PSP is to identify and pri-
ritise ‘treatment uncertainties’ [18], that are deﬁned as research
uestions about the effects of a healthcare intervention for which
here are no up-to-date, reliable, systematic reviews of research
vidence.
. Aims
The aim of this PSP was to identify the top 10 research priorities
elating to mesothelioma (pleural or peritoneal), and speciﬁcally
o identify those unanswered questions that involved an inter-
ention, in order to aid translation into immediately answerable
esearch questions. Thus detailed, rather than general, questions
ere required, which speciﬁed the intervention(s) to be tested
nd did not simply identify the need for research into a topic (e.g.
reathlessness).
. Methods
Priority setting methods have been established and used by
lmost 30 JLA PSPs, including prostate cancer [19], vitiligo [20],
alliative and end of life care [21], childhood neurodisability [22],
nd dystrophic epidermolysis bullosa [23]. Details of the meth-
ds agreed and adopted can be found in a number of publications
24–28], and therefore only a brief summary is presented here. Key
tages involve:
Establishing a Steering Group to deﬁne the scope of the partner-
ship and develop a protocol detailing the methods to be used.
Developing an initial survey questionnaire to gather a wide range
of experiences from patients, carers, and health professionals
about the diagnosis, treatment and care of patients.
Reviewing the survey responses, identifying unique ‘themes’ and
generating draft research questions.
Searching national guidelines, systematic reviews and ran-
domised trials to ensure that each research question has not
already been reliably answered.
Undertaking an interim prioritisation survey of patients, carers,
health professionals and support organisations to identify objec-
tively a shortlist of priorities.cer 89 (2015) 175–180
• Setting up a ﬁnal priority setting consensus meeting to rank all of
the questions on the shortlist, but in particular to agree the top
10 priorities.
• Adding all the identiﬁed unanswered questions to the UK
Database of Uncertainties about the Effects of Treatment (UK
DUETs), a web-based public information repository [29].
• An additional requirement of the mesothelioma PSP was to
include only interventional questions (i.e. questions that could be
formatted using a ‘PICO’ (Population-Intervention-Comparison-
Outcome) structure [30,31]). Any questions that did not satisfy
this criteria were deemed ‘out of scope’.
4. Results
The JLA Mesothelioma PSP Steering Group comprised two
patients, one bereaved carer, nine health professionals (includ-
ing nurses, surgeons, oncologists, chest physicians and palliative
care experts), and four representatives of patient and family sup-
port groups (one of the representatives was  also a bereaved carer).
The Steering Group was chaired by a JLA facilitator, coordinated
and supported by the NIHR Evaluation, Trials and Studies Coor-
dinating Centre (NETSCC), and also included representatives from
3 UK-based charities (the British Lung Foundation, Mesothelioma
UK, and the June Hancock Mesothelioma Research Fund), and an
information specialist. A launch meeting was held in December
2013.
Between February and April 2014, the initial survey, asking
whether responders “had ever had a question about the diagno-
sis, treatment or care of mesothelioma, and not been able to ﬁnd
the answer” was  circulated to known support organisations and
health professionals with a request that it be passed on to as many
interested parties as possible, as well as being made available on
various relevant websites. A total of 453 responses were returned
(including 103 from patients, 242 from carers, partners or relatives
of mesothelioma patients, 82 from health professionals, and the
remaining 26 from support organisations, and those who  either
did not indicate a category, or indicated they belonged to more
than one category). There was an excellent responder represen-
tation according to age, gender, location and health professional
specialty, with the majority (79%) of the patients who responded
being male, the majority (86%) of the carers being female, and only
5% of the patients (as identiﬁed by the patient themselves or their
carer) having peritoneal mesothelioma.
Although the survey asked for suggestions for research ques-
tions, most of the responses were written as personal stories, and
thus this subjective narrative text had to be transformed into objec-
tive questions. To do this, the 453 responses were all reviewed, and
‘themes’ (e.g. breathlessness, role of immunotherapy, GP aware-
ness, etc.) were listed. After merging similar themes, 98 separate
themes remained, and draft research questions were generated.
The draft questions were then reviewed to see whether they
involved an intervention, and were able to be written in a PICO
format. A total of 52 questions ﬁtted these criteria, whereas the
remaining 46 questions were considered ‘out of scope’ and will be
reported elsewhere.
In order to check that the draft research questions had not
already been reliably answered, a search was  made in May  2014
for relevant systematic reviews, (searching for ‘mesothelioma’ in
the Reviews section of the Cochrane Library, and for papers with
‘mesothelioma’ and ‘systematic review’ in their title in Pubmed).
A total of 30 were found, but only one [32] made a clear rec-
ommendation (‘that the addition of pemetrexed to cisplatin may
improve survival’) whilst most of the rest called for more trials to
provide reliable evidence. Therefore none of the 52 questions were
removed.
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Between August and September 2014, the interim prioritisation
urvey was circulated to 397 people who had previously indicated
heir interest in the project, asking them to rank the importance
f each of the 52 questions on a scale of one to ﬁve. There were
02 respondents and their responses were allocated to four sub-
roups depending on the type of responder: 38 patients, 98 carers,
0 health professionals and 16 support organisations. Within each
ubgroup the scores for each of the 52 questions were added, thus
reating a ranked list. The rank positions of each question in the
 subgroups were then added together, and the questions were
ut into interim order of priority. As is clear from online Table
 this interim prioritisation exercise reﬂected the differences in
nowledge, experience and concerns of patients, carers, and health
rofessionals. The Steering Group proposed that the top 30 ranked
uestions from the interim prioritisation survey be taken to the
orkshop for ﬁnal prioritisation, and these 30 questions were given
dentiﬁers A–Z and then AA–DD.
Thirty people (six mesothelioma patients, four carers, 16
ealth professionals [including surgeons, medical oncologists,
linical oncologists, palliative care and respiratory physicians,
nd specialist nurses], and four representatives of patient sup-
ort organisations) attended a ﬁnal consensus meeting on 10th
ovember 2014. Participants initially worked in three mixed
roups, each led by an independent JLA facilitator, to rank all 30
able 1
esothelioma top 10 research priority list (plus 3 highly recommend questions).
Rank Research question 
1 Does boosting the immune system (using new agents such as PD-1 or
PD-L1) improve response and survival rates for mesothelioma
patients?
2  Can individualised chemotherapy be given to mesothelioma patients
based on predictive factors (e.g. the subtype of mesothelioma
(epithelioid, sarcomatoid, or mixed), or thymidylate synthase inhibitor
status (the protein that drugs like pemetrexed act against), etc.)?
3  What is the best way to monitor patients with diffuse pleural
thickening and a negative biopsy who are considered to have a high
risk  of developing mesothelioma (e.g. repeat biopsies, imaging, etc.)?
4  In mesothelioma patients, what is the best second line treatment (i.e.
what chemotherapy drugs should be used if a cancer has recurred
following ﬁrst line chemotherapy, usually with cisplatin and
pemetrexed)?
5  Which is the most effective current treatment for ascites (excessive
accumulation of ﬂuid in the abdominal cavity) (e.g. peritonoevenous
shunt, tunnelled indwelling peritoneal catheter, etc.) in patients with
peritoneal mesothelioma?
6  What are the relative beneﬁts of immediate standard chemotherapy
compared to a watch and wait policy for mesothelioma patients?
7  For mesothelioma patients, what is the best follow-up strategy
post-treatment, to identify and treat emerging side effects and other
problems?
8  In mesothelioma, is there a role for intrapleural immunostimulants (a
drug designed to stimulate an anti-cancer immune response, such as
corynebacterium parvum extract) in addition to any other treatment?
9  Does an annual chest X-ray and/or CT scan and medical examination in
high-risk occupations (e.g. carpenters, plumbers, electricians, shipyard
workers) lead to earlier diagnosis of mesothelioma?
10  What, if any, are the beneﬁts of pleurectomy
(pleurectomy/decortication) compared to no surgery, and which
mesothelioma patients might beneﬁt?
11  Can PET scans (which produce 3D images of the inside of the body)
help to diagnose mesothelioma (as well as aiding the assessment of
response to treatment)?
12  How can the levels of mesothelin (a protein present in mesothelioma
cells that can be measured in the blood) best be incorporated in the
diagnosis, response and progression of mesothelioma?
13  What is the best current treatment for breathlessness in mesothelioma
patients (e.g. exercise, handheld fans, etc.)?cer 89 (2015) 175–180 177
questions, and the combined scores and ranks are displayed in
online Table B. There was a high level of agreement between the
three groups. The participants were then re-conﬁgured into three
new groups and asked to review the combined rankings, but made
only minor changes. However, at the ﬁnal plenary session there was
much discussion around:
• the generality of many of the questions and the relationship with
questions that had a more speciﬁc focus,
• questions that were not mesothelioma speciﬁc,
• symptoms and side effects that had multiple causes and multiple
treatments,
• questions that were dependent on other unanswered questions
(i.e. the value of chemotherapy before surgery, without knowing
the value of surgery),
• whether a question should be de-prioritised if the intervention to
be studied was  only appropriate for a small number of patients,
• whether peritoneal mesothelioma should be a separate category,
• whether the top 10 should aim to cover a portfolio of topics, and
• whether questions that were being addressed by ongoing trialsshould be included.
However, despite these discussions, the ranking of only four
questions was changed, and the meeting closed with a unanimous
Comments
The relative lack of success of chemotherapy, and the positive signs
from recent phase I trials, have shifted interest towards
immunotherapy.
Recent predictive factor analyses have revealed different responses to
pemetrexed for different histological subgroups, and this
individualising of treatment will develop with increasing analysis of
large databases.
Patients with pleural thickening are known to be at high risk of
developing mesothelioma.
Although most patients respond to 1st line chemotherapy, the effect is
usually short lived, and identiﬁcation of the best 2nd line treatment is
urgently needed.
A major symptom of peritoneal mesothelioma is the recurrent build
up  of ﬂuid in the abdominal cavity, which requires regular draining.
Finding the best way to do this would improve patients’ quality of life.
Given the small beneﬁt with chemotherapy, and the potential side
effects, there may  be a case for delaying treatment, in some patients.
Deﬁning the patients and the point at which to start treatment would
be  beneﬁcial.
Post-treatment survival is often measured in weeks, but patients are
often given 3 month follow-up appointments. What is the most
effective strategy to ensure quick treatment when symptoms and side
effects appear?
Delivering immuno-stimulants directly to the pleural or peritoneal
cavity may  be more effective than systemic (iv) treatments.
Is it cost-effective to try and identify and regularly screen workers in
high risk occupations?
The value of radical surgery has been called into question by the results
of  the MARS trial, but a less radical procedure might be beneﬁcial. The
planned MARS2 trial will attempt to answer this question.
Diagnosis, and monitoring changes in the disease, are currently mainly
done by CXR or CT, but using PET-CT scans might be more helpful.
Although mesothelin has been shown to be a useful marker, more
work is needed to improve the sensitivity and speciﬁcity of the test.
Breathlessness is the most common, and most debilitating, symptom
of mesothelioma, and yet little research has been done into ways to
relieve distress.
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onsensus on the top 10 research priorities, and a recommenda-
ion that a further three questions should be highlighted as being
orthy of consideration. Therefore these 13 questions are listed
n Table 1, along with indications of why they were considered
mportant.
. Discussion
There are numerous reasons why research into the diagnosis,
reatment and care of patients with mesothelioma is important.
he incidence of mesothelioma continues to rise, confounding ear-
ier predictions that the number of new cases in the UK would peak
round the turn of the century. However, even with over 2500 new
ases a year in the UK, the relative rarity of mesothelioma makes
t difﬁcult to run large randomised trials. The dearth of reliable
vidence about mesothelioma can be gauged from the fact that
earches in October 2014 (searching for ‘mesothelioma’ in the Trials
ection of the Cochrane Library, and for papers with ‘mesothelioma’
nd ‘randomised’ in their title in Pubmed) only identiﬁed a total of
8 relevant randomised trials (20 fully published, nine presented
t meetings, four completed, 12 ongoing and three planned but not
et started). For information, the 29 published and presented trials
re listed in Table 2.
The limited available evidence suggests that none of the usual
ncological modalities (surgery, radiotherapy and chemotherapy)
ave made much impression on improving survival rates or quality
f life. Thus new ideas and new incentives are required to investi-
ate and discover new effective treatments, and to support patients
hrough this distressing disease.It is therefore timely that this JLA PSP was set up to speciﬁ-
ally incorporate patients’, carers’ and health professionals’ views,
s Chalmers and Glasziou [33] have argued strongly for a more efﬁ-
ient research culture in which scientists study health conditions
able 2
ublished randomised trials in mesothelioma.
Summary 
Fully published papers
Doxorubicin vs cyclophosphamide
Platinum analogues JM8  vs JM9  
Cyclophosphamide/adriamycin ± imidazole carboxamide 
Cisplatin/mitomycin vs cisplatin/doxorubicin 
Local  radiotherapy 
Surgery ± intraoperative photodynamic therapy and postoperative
immunochemotherapy
Pemetrexed 
Radiotherapy for tract metastases 
Raltitrexed 
Early  vs delayed chemotherapy 
Intervention site radiotherapy 
Maintenance pemetrexed 
Active Symptom Control ± chemotherapy 
Aprotinin for blood loss 
Extra-pleural pneumonectomy (EPP) vs No EPP 
Bevacizumab 
Maintenance thalidomide 
VATS  pleurectomy vs talc 
Pemetrexed/cisplatin ± CBP501 
Nurse education 
Meeting abstracts
Onconase vs doxorubicin 
Interleukin-2 
ICE  ± hyperthermia 
Doxorubicin ± onconase 
Second line vorinostat 
Pemetrexed/gemcitabine vs pemetrexted/carboplatin 
Axitinib 
ADI-PEG20 vs placebo 
Hemithoracic radiotherapy post chemotherapy and surgery 
ote: Does not include trials which included a subset of mesothelioma patients.cer 89 (2015) 175–180
that address questions about interventions and outcomes that
patients and clinicians consider to be the most important.
Inevitably, such large collaborative projects raise numerous
issues, and a few aspects require greater discussion:
• Given the incapacitating symptoms and short survival, ﬁnding
patients to sit on the Steering Group was  a major challenge.
Although we were fortunate to involve two long-term survivors
(one of whom sadly died during the project), it could be argued
that they were not typical patients.
• Although attempts were made to formulate the research ques-
tions in lay language, in some situations it proved to be extremely
difﬁcult to do this in a concise fashion. This represented a major
challenge for most patients and carers and, at the ﬁnal work-
shop, many indicated they felt disadvantaged by their lack of
understanding of the complex medical issues.
• Mediating the contrast between patients’ expectations of speedy
and major progress, and clinicians’ and researchers’ awareness
that progress is slow and usually involves small cumulative steps,
proved difﬁcult.
• Total scores were generated for each question for both the initial
prioritisation survey, and the initial subgroup session of the ﬁnal
prioritisation workshop (see online Tables A and B). It may  appear
overly simplistic to add the positions together (as an outlying rank
may  skew the combined position), but, interestingly, alternative
options (taking the median score, or the highest score) give very
similar results, and thus it was  felt the method used was valid.
• The importance of some questions varied signiﬁcantly between
the initial and ﬁnal prioritisation lists, and Fig. 1 shows the
cross-tabulation of the initial and ﬁnal rank of each question.
The diagonal line indicates what the picture would have been
if the interim and ﬁnal ranks were identical, but as can be seen,
the rank position of some questions changed signiﬁcantly. This
Pts Reference
32 Sorensen et al. Cancer Treat Rep 1985;1431–2
16 Cantwell et al. Cancer Chemother Pharmacol 1986;286–8
76 Samson et al. JCO 1987;86–91
79 Chahinian et al. JCO 1993;1559–65
40 Boutin et al. Chest 1995;754–8
63 Pass et al. Ann Surg Oncol 1997;628–33
456 Vogelzang et al. JCO 2003;2636–44
58 Bydder et al. BJC 2004;9–10
250 van Meerbeeck et al. JCO 2005;6881–9
43 O’Brien et al. Ann Oncol 2006;270–5
61 O’Rourke et al. Rad Oncol 2007;18–22
243 Jassem et al. JCO 2008;1698–704
409 Muers et al. Lancet 2008;1685–94
20 Norman et al. Cancer 2009;833–41
50 Treasure et al. Lancet Oncol 2011;763–72
115 Kindler et al. JCO 2012;2509–15
222 Buikhuisen et al. Lancet Oncol 2013;543–51
196 Rintoul et al. Lancet 2014;1118–27
65 Krug et al. Lung Cancer 2014;429–34
177 Nagamatsu et al. Nurse Educ Today 2014;1087–93
157 Vogelzang et al. ASCO 2000;577a (abs 2274)
14 Pitako et al. ASCO 2003;230 (abs 920)
27 Bakhahandeh et al. ASCO 2004;685 (abs 7288)
413 Reck et al. ASCO 2009;383 (abs 7507)
660 Krug et al. EJC 2011;47(Suppl. 2):2–3
32 Millenson et al. ASCO 2010;28 (abs e18053)
26 Buikhuisen et al. ASCO 2013;31 (abs 7528)
68 Szlosarek et al. ASCO 2014;32 (abs 5707)
54 Stahel et al. abs ESMO 2014 (abs LBA37)
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Fig. 1. Comparison of interim vs ﬁnal ranking of top 30 questions. Note: the letters
(A–Z, and AA–DD) correspond to the 30 research questions (see online Tables A and
B),  and the ﬁgure indicates the change between the interim and ﬁnal prioritisation
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patients, carers and clinicians. BMJ  Support Palliat Care 2015;5:102.for  example question Q was  ranked 19th at the interim stage, but 1st in the ﬁnal
ist).
suggests that there was a gradual shift in emphasis over the suc-
cessive stages of the project, away from the more patient and
carer orientated concerns (e.g. fatigue) towards more complex
interventions.
At the ﬁnal workshop, trying to put every single question in order
of importance proved to be the most difﬁcult part of the process.
The discussion focused on the top 13 questions, and therefore it
might be better to consider these as a group of equally important
questions.
However, despite the above concerns this JLA PSP succeeded in
ts aim of bringing together patients, carers, and health profession-
ls to identify, discuss, and prioritise the important unanswered
esearch questions in mesothelioma. This rigorous, transparent
nd person-centred approach reﬂects what matters most to peo-
le affected by mesothelioma and health professionals dealing
ith this disease. The top 10 research priorities include a wide
ortfolio of potential research projects (including immunotherapy,
hemotherapy and surgery, as well as questions about the role of
ET scans, screening and monitoring patients, and the management
f ascites in peritoneal mesothelioma).
. Conclusions
The research priorities highlighted by this JLA PSP present clear
irections for future interventional research, and it is important
hat researchers and funders in the UK, and globally, take note of
his list and establish studies that will ultimately improve the expe-
ience and the current poor outlook of patients with mesothelioma.
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